NO20001555D0 - Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon - Google Patents

Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon

Info

Publication number
NO20001555D0
NO20001555D0 NO20001555A NO20001555A NO20001555D0 NO 20001555 D0 NO20001555 D0 NO 20001555D0 NO 20001555 A NO20001555 A NO 20001555A NO 20001555 A NO20001555 A NO 20001555A NO 20001555 D0 NO20001555 D0 NO 20001555D0
Authority
NO
Norway
Prior art keywords
threonine protein
azabenzimidazole
protein kinase
serine
based compounds
Prior art date
Application number
NO20001555A
Other languages
English (en)
Other versions
NO325663B1 (no
NO20001555L (no
Inventor
Gerald Mcmahon
Heinz Weinberger
Bernard Kutscher
Harald App
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO20001555L publication Critical patent/NO20001555L/no
Publication of NO20001555D0 publication Critical patent/NO20001555D0/no
Publication of NO325663B1 publication Critical patent/NO325663B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20001555A 1997-09-26 2000-03-24 Azabenzimidazolbaserte forbindelser, fremgangsmater for fremstilling av forbindelsene, anvendelse av forbindelsene samt farmasoytiske sammensetninger inneholdende forbindelsene NO325663B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26
PCT/US1998/019973 WO1999016438A1 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (3)

Publication Number Publication Date
NO20001555L NO20001555L (no) 2000-03-24
NO20001555D0 true NO20001555D0 (no) 2000-03-24
NO325663B1 NO325663B1 (no) 2008-07-07

Family

ID=22027657

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001555A NO325663B1 (no) 1997-09-26 2000-03-24 Azabenzimidazolbaserte forbindelser, fremgangsmater for fremstilling av forbindelsene, anvendelse av forbindelsene samt farmasoytiske sammensetninger inneholdende forbindelsene

Country Status (28)

Country Link
US (2) US6093728A (no)
EP (1) EP1017384B1 (no)
JP (1) JP2001517699A (no)
KR (1) KR100547929B1 (no)
CN (1) CN1167420C (no)
AR (1) AR017266A1 (no)
AT (1) ATE281834T1 (no)
AU (1) AU748849B2 (no)
BG (1) BG64784B1 (no)
BR (1) BR9812682A (no)
CA (1) CA2305370C (no)
DE (1) DE69827516T2 (no)
DK (1) DK1017384T3 (no)
ES (1) ES2230719T3 (no)
HK (1) HK1032206A1 (no)
HU (1) HUP0004024A3 (no)
IL (4) IL135109A0 (no)
NO (1) NO325663B1 (no)
NZ (2) NZ503432A (no)
PL (1) PL191618B1 (no)
PT (1) PT1017384E (no)
RU (1) RU2230553C2 (no)
SK (1) SK285357B6 (no)
TR (1) TR200001546T2 (no)
TW (1) TW581815B (no)
UA (1) UA72448C2 (no)
WO (1) WO1999016438A1 (no)
ZA (1) ZA988797B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
CZ20032691A3 (en) * 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
WO2007062222A2 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
JP2009534457A (ja) 2006-04-26 2009-09-24 キャンサー・リサーチ・テクノロジー・リミテッド がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体
KR101504669B1 (ko) 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US8748371B2 (en) * 2007-02-28 2014-06-10 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
PE20090370A1 (es) * 2007-06-05 2009-04-30 Takeda Pharmaceutical Derivados de heterociclo fusionado como inhibidores de quinasa
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
UA105763C2 (uk) 2007-12-19 2014-06-25 Кансер Рісерч Текнолоджі Лімітед 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010025448A2 (en) * 2008-08-29 2010-03-04 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
NZ618135A (en) 2009-10-26 2015-05-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CA2786834C (en) 2010-02-01 2018-10-16 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
MX357833B (es) 2011-10-19 2018-07-26 Signal Pharm Llc Tratamiento del cancer con inhibidores de tor cinasa.
AU2012304276B2 (en) 2011-12-02 2015-01-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
MY174308A (en) 2012-02-24 2020-04-06 Signal Pharm Llc Methods for treating non-small cell lung using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
ES2717446T3 (es) 2013-09-17 2019-06-21 Yeda Res & Dev Péptidos derivados de ERK y usos de los mismos
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP4289822A3 (en) 2014-09-12 2024-01-24 Biohaven Therapeutics Ltd. Benzoimidazol-1,2-yl amides as kv7 channel activators
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de) * 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) * 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2140440A1 (en) * 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
NO325663B1 (no) 2008-07-07
US20030181480A1 (en) 2003-09-25
KR20010015623A (ko) 2001-02-26
BR9812682A (pt) 2000-08-22
NO20001555L (no) 2000-03-24
RU2230553C2 (ru) 2004-06-20
AU748849B2 (en) 2002-06-13
CN1167420C (zh) 2004-09-22
HUP0004024A3 (en) 2001-10-29
CA2305370C (en) 2006-11-28
EP1017384A1 (en) 2000-07-12
CN1278172A (zh) 2000-12-27
ES2230719T3 (es) 2005-05-01
SK4152000A3 (en) 2002-02-05
IL158649A (en) 2006-12-10
SK285357B6 (sk) 2006-11-03
US6855723B2 (en) 2005-02-15
PL339744A1 (en) 2001-01-02
CA2305370A1 (en) 1999-04-08
DE69827516D1 (de) 2004-12-16
IL158649A0 (en) 2004-05-12
UA72448C2 (en) 2005-03-15
KR100547929B1 (ko) 2006-02-02
HUP0004024A2 (hu) 2001-04-28
HK1032206A1 (en) 2001-07-13
IL135109A0 (en) 2001-05-20
TW581815B (en) 2004-04-01
EP1017384B1 (en) 2004-11-10
JP2001517699A (ja) 2001-10-09
US6093728A (en) 2000-07-25
DE69827516T2 (de) 2005-12-01
PL191618B1 (pl) 2006-06-30
ATE281834T1 (de) 2004-11-15
AU9578198A (en) 1999-04-23
TR200001546T2 (tr) 2000-10-23
ZA988797B (en) 1999-12-02
AR017266A1 (es) 2001-09-05
IL135109A (en) 2007-07-04
WO1999016438A1 (en) 1999-04-08
NZ517808A (en) 2003-07-25
DK1017384T3 (da) 2005-01-31
PT1017384E (pt) 2005-03-31
BG104356A (en) 2000-12-29
BG64784B1 (bg) 2006-04-28
NZ503432A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
NO20001555D0 (no) Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon
MXPA03011007A (es) Metodos para modular la funcion de serina/treonona proteina cinasa por compuestos basados en 5-azaquinoxalina.
WO2002096867A3 (en) Inhibitors of protein kinase for the treatment of disease
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
ATE248170T1 (de) Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
DE60227492D1 (de) Hemmstoffe der akt aktivität
ATE324877T1 (de) Behandlung von metastatischer krankheit
TR200402157T2 (tr) Heteroaril süksinamidler ve metalloproteinaz inhibitörü olarak kullanımları
EA200100992A1 (ru) Ингибиторы фермента impdh
ATE26835T1 (de) Tris(piperidylaminotriazylamino) verbindungen, ihre herstellung und ihre verwendung als stabilisierungsmittel fuer polymere.
ATE461179T1 (de) Hemmer der akt aktivität
EA200100139A1 (ru) Фармацевтические композиции, содержащие 2-хинолоны
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
WO1999050269A3 (de) Porphyrine und ihre verwendung als phptosensitizer
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BR0016547A (pt) Composição para a modulação e inibição da permeabilidade vascular (vp)
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
WO2003033499A3 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
DE69804125D1 (de) Verwendung von immunomodulatoren
EA200000092A1 (ru) Противоаллергические средства
DK162839C (da) N,3-diacyl-2-oxindol-1-carboxamid-forbindelser og 3-acyl-2-oxindol-forbindelser til anvendelse som mellemprodukter ved deres fremstilling
DE60008378D1 (de) Ledergerben
PA8478901A1 (es) Isoquinolinas
WO2005077983A3 (en) Modulating p38 kinase activity